Neuralstem (CUR) Price Target Lowered to $1.91 at S&P Equity Research

Neuralstem (NASDAQ:CUR) had its target price lowered by analysts at S&P Equity Research from $2.26 to $1.91 in a report released on Thursday.

Shares of Neuralstem (NASDAQ:CUR) traded up $0.09 during mid-day trading on Thursday, reaching $1.91. The company’s stock had a trading volume of 504,100 shares, compared to its average volume of 328,714. Neuralstem has a one year low of $0.88 and a one year high of $6.60. The firm has a market cap of $33.98, a price-to-earnings ratio of -1.15 and a beta of 1.60.

An institutional investor recently raised its position in Neuralstem stock. National Asset Management Inc. increased its position in Neuralstem, Inc. (NASDAQ:CUR) by 9.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,985 shares of the company’s stock after buying an additional 1,937 shares during the quarter. National Asset Management Inc. owned about 0.19% of Neuralstem worth $134,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/01/11/neuralstem-cur-price-target-lowered-to-1-91-at-sp-equity-research.html.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply